Cerimon receives positive Phase II data on diclofenac patch
This article was originally published in Scrip
Executive Summary
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
You may also be interested in...
Lilly's Alimta among SMC's September recommendations
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.
Retroscreen Virology receives €630,000 to start first clinical study of avian influenza vaccine
The UK CRO Retroscreen Virology is planning to start its first clinical study of a novel, culture-based intranasal vaccine against diverse strains of avian influenza (H5N1), along with other members of a European consortium. Other consortium members include Archimedes Development, the University of Leicester, the National Institute of Biological Standards Control, and Evicom.